Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis

The anti-angiogenic drug Bevacizumab (Bev) is engaged in neoadjuvant therapy for non-metastatic breast cancer (NMBC). However, whether neoadjuvant Bev providing a greater benefit to patients is debatable. Our study aimed to review Bev's role in Neoadjuvant therapy (NAT) in NMBC and identify pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, XinJie, Gao, Yu, Zhang, GanLin, Li, BingXue, Ma, TingTing, Ma, YunFei, Wang, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040714/
https://www.ncbi.nlm.nih.gov/pubmed/33854624
http://dx.doi.org/10.7150/jca.53303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040714/
https://www.ncbi.nlm.nih.gov/pubmed/33854624
http://dx.doi.org/10.7150/jca.53303

Ejemplares similares